STAT and The Harris Poll asked U.S. adults about their interest in new weight-loss drugs like Ozempic and their thoughts on pricing.June 26, 2023Check out STAT+Sponsored By Mario Tama/Getty Images STAT+ | STAT-Harris Poll: Nearly half of U.S. adults would spend $100 a month for Ozempic, other weight-loss drugs STAT and The Harris Poll asked U.S. adults about their interest in new weight-loss drugs like Ozempic and their thoughts on pricing. By Ed Silverman and Elaine Chen STAT+ | UnitedHealth wins $3.3 billion takeover of home health giant Amedisys Amedisys and UnitedHealth Group's Optum agreed to a deal Monday in which UnitedHealth will pay $3.3 billion total for Amedisys. By Bob Herman STAT+ | Shareholders elect director's romantic partner to Biogen's board Susan Langer, the romantic partner of departing director Alex Denner, will join the eight-member board for a one-year term. By Damian Garde and Adam Feuerstein Kiera Hight for STAT 'I felt like I was dying': How women with postpartum depression fall through the cracks of U.S. health care Postpartum depression, the most common childbirth complication, affects one in every seven new mothers. Half the cases go undiagnosed. By Katharine Gammon STAT+ | In setback, Pfizer abandons one weight-loss pill and bets on another The move by the drug giant to abandon the once-daily pill, lotiglipron, is seen as a setback by investors. By Matthew Herper More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Daily Recap? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments